Dyslipidemia Drug Indications

Share this content:
DYSLIPIDEMIA DRUG INDICATIONS
DYSLIPIDEMIA DRUG INDICATIONS
Generic Brand Form Indications
Slow
coronary
athero-
sclerosis
Lower
total-C
Lower
LDL-C
Increase
HDL-C
Lower
apo B
Lower
TG
Sitosterol/
campe-
sterol
Reduce
risk of
CVD4
BILE ACID SEQUESTRANTS
cholestyr-
amine resin
pwd



 
colesevelam Welchol tabs,
oral susp







colestipol Colestid tabs,
granules






CHOLESTEROL ABSORPTION INHIBITOR
ezetimibe Zetia tabs


2
FIBRATES
fenofibrate Antara caps


Fenoglide tabs



Lipofen caps


Lofibra tabs, caps


Tricor tabs


Triglide tabs


fenofibric acid Fibricor tabs


Trilipix del-rel caps


LIPID-REGULATING AGENT
gemfibrozil Lopid scored tabs 1




icosapent ethyl Vascepa caps






omega-3-acid
ethyl esters
Lovaza caps






MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITOR
lomitapide mesylate Juxtapid caps
3



NICOTINIC ACID DERIVATIVES
niacin Niaspan ext-rel tabs
OLIGONUCLEOTIDE INHIBITOR
mipomersen Kynamro SC inj
3



PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) INHIBITOR
alirocumab Praluent SC inj






evolocumab Repatha SC inj






Repatha Pushtronex SC inj


STATINS (HMG-CoA REDUCTASE INHIBITORS)
atorvastatin Lipitor tabs

fluvastatin Lescol caps
Lescol XL ext-rel tabs
lovastatin tabs

Altoprev ext-rel tabs
pitavastatin Livalo tabs


pravastatin Pravachol tabs
rosuvastatin Crestor tabs 3
simvastatin Zocor tabs

STATIN + CALCIUM CHANNEL BLOCKER
atorvastatin +
amlodipine
Caduet tabs

STATIN + CHOLESTEROL ABSORPTION INHIBITOR
simvastatin +
ezetimibe
Vytorin tabs


Classification of Hyperlipoproteinemias
Fredrickson Type    Elevated Lipoproteins     Lipid Elevations (Major)      Lipid Elevations (Minor)
I (rare) chylomicrons triglycerides total-C elevated or no change
IIa LDL total-C
IIb LDL, VLDL total-C triglycerides
III (rare) IDL total-C/triglycerides
IV VLDL triglycerides total-C elevated or no change
V chylomicrons, VLDL triglycerides total-C elevated or no change
NOTES

Key:  apo B = apolipoprotein B;  TG = triglycerides;  total-C = total cholesterol;  LDL-C = low-density lipoproteins;  CVD = cardiovascular disease;  IDL = intermediate-density lipoproteins;  VLDL = very low density lipoproteins;  HDL-C = high-density lipoproteins

1 Reduction in risk of coronary artery disease when first line agent is inadequate

2 To reduce elevated sitosterol and campesterol in homozygous familial sitosterolemia

3 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

4 To reduce risk of: MI, stroke, or coronary revascularization procedures, and morbidity/mortality.

FDA-approved indications marked with a ✓. Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. Listed indications may be adjuncts to other therapies, lifestyle changes and/or concomitant drugs.

(Rev. 3/2017)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs